Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized colistin vs colistin + fosfomycin for ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii
IRCT20171230038142N12Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Aug 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of colistin and fosfomycin in ventilator-associated pneumonia (VAP) and multidrug-resistant Acinetobacter baumannii infection (2 arms), sponsored by Isfahan University of Medical Sciences. Started Aug 2019; status: completed.
02
Drugs
colistinfosfomycin
03
Conditions
ventilator-associated pneumonia (VAP)multidrug-resistant Acinetobacter baumannii infection
Beyond the preview
Go deeper on IRCT20171230038142N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171230038142N12.